Subject: Re: Novo Nordisk $NVO. (x-post)
Iown a little purchased at arpund $40 toe dip.

I'll share my LLM discussion.

Why NVO stock is under pressure (2026)

1) Weak 2026 outlook (biggest driver)

The company shocked investors by forecasting sales & profit decline of ~5%–13% in 2026 �
Yahoo Finance +1

This is a major shift from years of strong growth → markets repriced the stock lower

👉 In simple terms: investors went from “high-growth story” → “possible downturn”

2) Intense competition (especially from Eli Lilly)
Rival drugs like Zepbound / tirzepatide are:
Seen as more effective in weight loss
Rapidly gaining market share �
Kavout
New launches (including oral pills) are heating up the fight �
Reuters

👉 The market now thinks Novo’s dominance in obesity drugs is no longer guaranteed

3) Falling drug prices (margin pressure)
US pricing pressure + government policies forcing lower prices �
Investing.com UK
Novo is even:
Offering discounted subscriptions
Planning price cuts to stay competitive �
Reuters +1

👉 Lower prices = lower profit per patient

4) Insurance & demand uncertainty
Many insurers are restricting coverage for weight-loss drugs �
Business Insider

That creates:
Demand volatility
Reliance on self-pay customers
👉 The growth story becomes less predictable

5) Patent expiries & copycat drugs
Semaglutide (key ingredient in Ozempic/Wegovy) facing:
Patent expiries in some markets
Cheaper alternatives / compounding �
Kavout

👉 More competition → pricing power weakens

6) Negative sentiment & downgrades
Analysts downgraded the stock due to:
trial setbacks
price wars

Seeking Alpha